2021 Annual Meeting Startup & Practice Management Access Pass-Treatment of human bone marrow concentrate and bone marrow stem cells with senolytic agents

Treatment of human bone marrow concentrate and bone marrow stem cells with senolytic agents

Video Transcription

Video Summary

In this video, Katie Whitney, an MPH student in epidemiology and research specialist at the Stem and Filpon Research Institute, discusses innovative methods to improve the cell function of bone marrow aspirate concentrate (BMAC) and bone marrow-derived stem cells. Post-traumatic osteoarthritis is increasing in young adults, and orthobiologics have been used to reduce chronic inflammation. However, there is currently no consensus on the efficacy of BMAC for musculoskeletal tissue treatment. Aging and injury impact tissue regenerative potential through cellular decline and senescence. Whitney's group is investigating therapeutic approaches to improve musculoskeletal healing and delay osteoarthritis by removing senescent cells and inhibiting senescence-associated secretory phenotype factors. They are conducting clinical trials using the senolytic agent facet and in combination with BMAC. Validation and development of senescence detection using C12 FDG in bone marrow and peripheral blood are being explored. The study aims to detect senescence, remove senescent cells, and improve cell function in BMAC and mesenchymal stem cells. The ultimate goal is to support healthy aging in orthopedics.

Asset Caption

Dr. Kaitie Whitney

Meta Tag

Concept Cell Senescence

Concept Bone Marrow Aspirate Concentrate

Concept Bone Marrow-Derived Mesenchymal Stem Cell

Concept Senolytic Agent

Concept Fisetin

Keywords

Katie Whitney

epidemiology

bone marrow aspirate concentrate

musculoskeletal tissue treatment

senescence

Cell Senescence

Bone Marrow Aspirate Concentrate

Bone Marrow-Derived Mesenchymal Stem Cell

Senolytic Agent

Fisetin